immune-checkpoint-inhibitor

Documents about immune-checkpoint-inhibitor

• Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]#851739ClinicalTrials.gov
• Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study#146466ClinicalTrials.gov
• Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial#839207ClinicalTrials.gov
• Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers#872895ClinicalTrials.gov
• Table 1_Efficacy and safety of combined immune therapy for advanced cervical cancer: a systematic review and meta-analysis.docx#222486Figshare
• The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis#388095HAL (France)
• A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients#444886ClinicalTrials.gov
• Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma#125850ClinicalTrials.gov
• Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma#851472ClinicalTrials.gov
• Dietary Intervention for NSCLC Patients Treated With ICI#1030857ClinicalTrials.gov
• Non-pharmacological supportive care interventions during immunotherapy for people with cancer: A systematic scoping review and future directions#977228Research Online
• Clinical utility of diagnosing Lynch syndrome in gynecologic oncology: a joint statement from four Japanese academic societies#477041OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas#855865ClinicalTrials.gov
• Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC#896675ClinicalTrials.gov
• Cancer Panel From Blood of Lung Cancer Patients#900850ClinicalTrials.gov
• Nivolumab in Children and Adults With Nasopharyngeal Carcinoma#893983ClinicalTrials.gov
• Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors#966970ClinicalTrials.gov
• A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer#896424ClinicalTrials.gov
• Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma#837592ClinicalTrials.gov
• Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response#845838ClinicalTrials.gov
• Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)#828325ClinicalTrials.gov
• Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN#852664ClinicalTrials.gov
• PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes#320317IRIS
• Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers#891741ClinicalTrials.gov
• Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)#905792ClinicalTrials.gov
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform#121327ClinicalTrials.gov
• How to best exploit immunotherapeutics in advanced gastric cancer: between biomarkers and novel cell-based approaches#250634IRIS
• Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer#843388ClinicalTrials.gov
• Neoadjuvant chemo-immunotherapy in a kidney transplant recipient with locally advanced non-small cell lung cancer: a case report of a therapeutic dilemma#308243HAL (France)
• FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors#872147ClinicalTrials.gov
• Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients#842297ClinicalTrials.gov
• Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of patients with non-small cell lung cancer with brain metastases at diagnosis.#676991HAL (France)
• Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy#806141ClinicalTrials.gov
• Risk factors for immune checkpoint inhibitor colitis: a retrospective multi-center cohort study using electronic health records#620193eScholarship
• Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI#846956ClinicalTrials.gov
• A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer#993319ClinicalTrials.gov